Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Open accessThe DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.
Abstract
Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy administered intravenously escape renal clearance, are unable to penetrate through tight endothelial junctions of normal blood vessels and remain at a high level in plasma. Over time, the concentration of nanodrugs builds up in tumors due to the EPR effect, reaching several times higher than that of plasma due to the lack of lymphatic drainage. This review will address in detail the progress and prospects of tumor-targeting via EPR effect for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The two phenomena of extravasation and later diffusion and convection of the colloid in the extracellular matrix both result in enhanced permeation and retention of the nanoparticles [32].](https://figures.cochat.ai/paper-figures/887ab73c266443efbb3420cd636da176/recent-advances-in-tumor-targeting-via-epr-effect-for-cancer-treatment-figure-1.jpg)
![Figure 2 Common strategies utilizing the EPR effect [109].](https://figures.cochat.ai/paper-figures/89ba4512a64543b1a593fb62b3bf1725/recent-advances-in-tumor-targeting-via-epr-effect-for-cancer-treatment-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In clinical settings, one of the main challenges for the delivery of macromolecules and nanomedicine to the cancer site is due to the heterogeneity of the EPR effect in solid tumors [20].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have demonstrated that only 0.1 to 0.2% of the injected dose is efficient against tumor cells and exhibits significant anticancer effects [20,123,161].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873 · cited 1×
“The rapid tumor growth and improper development of blood vessels in murine tumors result in a much leakier vasculature as compared to human tumors that can lead to misinterpretation of the EPR effect [78].”
BackgroundDoxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 1×
“The liposomal doxorubicin extravasated and accumulated intact in tumors with a leaky vasculature [79].”
BackgroundNanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 1×
“To date, the FDA has approved many other liposomal formulations such as DaunoXome®, which contains daunorubicin, and Marquibo®, which contains vincristine sulfate for cancer therapy [123] as well as other types of nanoparticle including polymeric micelles containing paclitaxel (Genexol® PM), micelles built with PEG an…”
BackgroundFactors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699 · cited 1×
“The physicochemical properties of any external material for therapeutic or diagnostic purposes are important in drug delivery as they impact the way the host defense mechanisms clear them from the systemic circulation [57,58].”
BackgroundLiposome: classification, preparation, and applications
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013) · Nanoscale Research Letters · doi:10.1186/1556-276x-8-102 · Cited by 3,632
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180 · cited 3×
“They also depend on what stage the cancer is and the site it is located at [26,27,39].”
BackgroundNanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039 · cited 1×
“These nanoparticles with a size below 50 nm are mostly used for the detection of brain tumors [140].”
REJMAN, J., OBERLE, V., ZUHORN, I. S., & HOEKSTRA, D. (2004) · Biochemical Journal · doi:10.1042/bj20031253 · Cited by 2,864 · cited 1×
“and spleen, but large enough to avoid kidney clearance [7,8].”
BackgroundBertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765 · cited 1×
“Combination of Abraxane with gemcitabine for the treatment of metastatic PDAC, and a combination of abraxane with carboplatin for the treatment of NSCLC have shown promise in the clinic [160].”
BackgroundRegulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438 · cited 1×
“They also depend on what stage the cancer is and the site it is located at [26,27,39].”
BackgroundSelf-citationAccumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429 · cited 1×
“• Nanoparticles smaller than 70 nm tend to aggregate in the tumor if they are highly permeable [60].”
BackgroundMaeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376 · cited 1×
“Formed micelles were about 80 nm in diameter and produced a clear tumor image similar to BSA-TRIC conjugate [139].”
BackgroundProgress and challenges towards targeted delivery of cancer therapeutics
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-03705-y · Cited by 2,220
Liposomal Formulations in Clinical Use: An Updated Review
Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020012 · Cited by 2,156 · cited 1×
“To date, the FDA has approved many other liposomal formulations such as DaunoXome®, which contains daunorubicin, and Marquibo®, which contains vincristine sulfate for cancer therapy [123] as well as other types of nanoparticle including polymeric micelles containing paclitaxel (Genexol® PM), micelles built with PEG an…”
BackgroundThe Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144 · cited 1×
“Besides increasing vascular leakiness, radiotherapy can prompt MDR and metastasis [150].”
BackgroundUlbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689 · cited 1×
“They also depend on what stage the cancer is and the site it is located at [26,27,39].”
BackgroundPrinciples and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675 · cited 3×
“The n w blood vessels being formed are disordered and discontinuous with many fenestr tions [38].”
BackgroundNormalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605 · cited 1×
“CPX-1 is a liposome containing irinotecan and fluoxuridine in a 1:1 molar ratio enhanced EPR-accumulation of CPX-1 in colorectal cancer [159].”
BackgroundNanocarriers’ entry into the cell: relevance to drug delivery
Hillaireau, H., & Couvreur, P. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0053-z · Cited by 1,552
Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,485 · cited 1×
“This happens due to the affinity of these macrophages to the colloids resulting in increased phagocytic activity [46].”
BackgroundMachtay, M., Moughan, J., Trotti, A., Garden, A. S., Weber, R. S., Cooper, J. S., Forastiere, A., & Ang, K. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8841 · Cited by 1,371 · cited 1×
“However, un-encapsulated nanodrugs, when combined with radiotherapy, may have severe side effects [149].”
BackgroundDrug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.015 · Cited by 1,288 · cited 1×
“The basement membrane (BM) and extracellular matrix (ECM) also play an important role in determining the porosity and stiffness of human tumors that lead to heterogenous penetration, poor prognosis, and treatment failure [66].”
BackgroundTumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262 · cited 8×
“In many liposomal and micellar nanodrug formulations, surface modification with the stealthy polymer, PEG, decreased aggregation, opsonization with plasma protein and enhanced the circulation half-life [20].”
BackgroundInfluentialMaeda, H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.002 · Cited by 1,179 · cited 2×
“The resulting hypoxic parts of tumors alter the EPR effect by activation of fibrinolysis, clotting, or bleeding in some tumor parts, result in poor delivery of drugs [65,71].”
BackgroundRole of extracellular matrix assembly in interstitial transport in solid tumors.
Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., & Jain, R. K. (2000) · PubMed · Cited by 1,165
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150 · cited 7×
“ADC might overcome heterogeneity of tumors by utilizing TME to facilitate cleavage of linkers and payload release [16].”
BackgroundInfluentialChauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Attia, M. F., Anton, N., Wallyn, J., Omran, Z., & Vandamme, T. F. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13098 · Cited by 1,085 · cited 1×
“Table 3 shows some selected EPR-based drug delivery systems [173].”
BackgroundTargeting the tumour stroma to improve cancer therapy
Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084 · cited 2×
“Therefore, novel anticancer therapies should be a combination of anticancer and anti-stroma therapeutic agents [9].”
BackgroundMethodChauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031 · cited 1×
“For example, losartan can decompress tumor blood vessels, increase vascular perfusion and EPR-targeted drug delivery [145].”
BackgroundA review on phospholipids and their main applications in drug delivery systems
Li, J., Wang, X., Zhang, T., Wang, C., Huang, Z., Luo, X., & Deng, Y. (2015) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2014.09.004 · Cited by 1,003 · cited 1×
“As stealth liposomes, the appropriate size of the liposomes prevents loss due to renal filtration, while pegylation, in turn, ensures that the RES system does not recognize the nanoparticles, which leads to the preferential accumulation of liposomes in tumor tissues through the EPR effect [121,122].”
BackgroundPolymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release
Oerlemans, C., Bult, W., Bos, M., Storm, G., Nijsen, J. F. W., & Hennink, W. E. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0233-4 · Cited by 947 · cited 1×
“To date, the FDA has approved many other liposomal formulations such as DaunoXome®, which contains daunorubicin, and Marquibo®, which contains vincristine sulfate for cancer therapy [123] as well as other types of nanoparticle including polymeric micelles containing paclitaxel (Genexol® PM), micelles built with PEG an…”
BackgroundMaeda, H., Sawa, T., & Konno, T. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00309-1 · Cited by 925
Tumor Vascular Permeability, Accumulation, and Penetration of Macromolecular Drug Carriers
Dreher, M. R., Liu, W., Michelich, C. R., Dewhirst, M. W., Yuan, F., & Chilkoti, A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj070 · Cited by 920 · cited 1×
“3 to 10 kDa with 2 and 3 nm diffused deeper into the tumor compared to the large molecules [59].”
BackgroundShi, Y., van der Meel, R., Chen, X., & Lammers, T. (2020) · Theranostics · doi:10.7150/thno.49577 · Cited by 868 · cited 1×
“Active targeting can also be used as a complementary approach to EPR-mediated tumor targeting to enhance drug delivery, accumulation, and retention in tumors [174].”
BackgroundTransport of molecules across tumor vasculature
Jain, R. K. (1987) · CANCER AND METASTASIS REVIEW · doi:10.1007/bf00047468 · Cited by 866
Cancer cells compress intratumour vessels
Padera, T. P., Stoll, B. R., Tooredman, J. B., Capen, D., Tomaso, E. D., & Jain, R. K. (2004) · Nature · doi:10.1038/427695a · Cited by 857 · cited 2×
“Thus, reduced pressure can lead to decreased convective forces and increased extravasation of both blood components and nanoparticles [26,28,38].”
BackgroundNichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834
Macromolecular therapeutics in cancer treatment: The EPR effect and beyond
Maeda, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.038 · Cited by 814 · cited 1×
“Accumulation by EPR in tumors can be enhanced with Angiotensin II receptor blockers (ARB) that promote vessel permeability and dilation through the loosening of the endothelial cadherin-mediated intracellular connections [53].”
BackgroundThe physiology of the lymphatic system
Swartz, M. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00150-8 · Cited by 737 · cited 3×
“The browninan motion of the blood colloids creates a positive net flux towards the interstitium when a gradient occurs between vascular (Cv) and interstitial concentrations (Ci) [30].”
BackgroundDiop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733 · cited 1×
“Preclinical models have shown increased accumulation and retention of the nanoparticles and oncolytic viruses with these approaches [45,49,50].”
BackgroundThe journey of a drug-carrier in the body: An anatomo-physiological perspective
Bertrand, N., & Leroux, J.-C. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.098 · Cited by 707 · cited 1×
“The physicochemical properties of any external material for therapeutic or diagnostic purposes are important in drug delivery as they impact the way the host defense mechanisms clear them from the systemic circulation [57,58].”
BackgroundSMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy
Maeda, H. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00134-4 · Cited by 662
Mas-Moruno, C., Rechenmacher, F., & Kessler, H. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152010794728639 · Cited by 647 · cited 1×
“Cligentide can bind to αvβ3 integrins to prompt anti-angiogenesis [146].”
BackgroundInterstitial Flow and Its Effects in Soft Tissues
Swartz, M. A., & Fleury, M. E. (2007) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.9.060906.151850 · Cited by 598 · cited 1×
“Unlike normal tissues, the tumor microenvironment has solutes, proteins, and debris distributed unevenly [30,40].”
BackgroundIntegrin-linked kinase: a cancer therapeutic target unique among its ILK
Hannigan, G., Troussard, A. A., & Dedhar, S. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1524 · Cited by 589
Lee, T. K. W., Castilho, A., Cheung, V. C. H., Tang, K. H., Ma, S., & Ng, I. O. L. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.06.005 · Cited by 586
Passive and Active Drug Targeting: Drug Delivery to Tumors as an Example
Torchilin, V. P. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_1 · Cited by 573
Self-citationHPMA copolymer–anticancer drug conjugates: design, activity, and mechanism of action
Kopecek, J. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00075-8 · Cited by 562 · cited 1×
“Conjugates of HPMA copolymer with an anticancer drug are active in many models and have low immunogenicity, which makes it possible to improve such a conjugate to target and control its subcellular localization of the drug based on its mechanism of action [116,118,119].”
BackgroundCooke, V. G., LeBleu, V. S., Keskin, D., Khan, Z., O'Connell, J. T., Teng, Y., Duncan, M. B., Xie, L., Maeda, G., Vong, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.024 · Cited by 530
Meng, H., Xue, M., Xia, T., Ji, Z., Tarn, D. Y., Zink, J. I., & Nel, A. E. (2011) · ACS Nano · doi:10.1021/nn200809t · Cited by 509
Ye, D., Shuhendler, A. J., Cui, L., Tong, L., Tee, S. S., Tikhomirov, G., Felsher, D. W., & Rao, J. (2014) · Nature Chemistry · doi:10.1038/nchem.1920 · Cited by 492 · cited 1×
“This combination therapeutic approach enhances the impact of individual drug components, aids synergistic effects, reduces side effects due to the encapsulation of drugs into a nanocarrier resulting in an enhanced nano-immunotherapeutic outcome [164].”
BackgroundMaeda, H., & Khatami, M. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0185-6 · Cited by 491 · cited 1×
“Thus, complete control and performance monitoring throughout therapy might help develop successful clinical trials [69,70].”
BackgroundChauhan, V. P., Popović, Z., Chen, O., Cui, J., Fukumura, D., Bawendi, M. G., & Jain, R. K. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201104449 · Cited by 473
Noguchi, Y., Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T., & Maeda, H. (1998) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1998.tb00563.x · Cited by 470
Eggermont, A. M. M., Koops, H. S., Klausner, J. M., Kroon, B. B. R., Schlag, P. M., Liénard, D., van Geel, A. N., Hoekstra, H. J., Meller, I., Nieweg, O. E., et al. (1996) · Annals of Surgery · doi:10.1097/00000658-199612000-00011 · Cited by 460
Duan, X., Chan, C., Guo, N., Han, W., Weichselbaum, R. R., & Lin, W. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b09538 · Cited by 458 · cited 1×
“An EGFR-targeted nanobody linked to a polymeric micelle (PM), nanobody modified DOX-PM, inhibited tumor growth and prolonged survival [162].”
BackgroundCharacterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature.
Kong, G., Braun, R. D., & Dewhirst, M. W. (2001) · PubMed · Cited by 442
Dimcevski, G., Kotopoulis, S., Bjånes, T., Hoem, D., Schjøtt, J., Gjertsen, B. T., Biermann, M., Molven, A., Sorbye, H., McCormack, E., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.10.007 · Cited by 434 · cited 1×
“Sonoporation in combination with gemcitabine-based therapy in pancreatic cancer demonstrated positive impact [153].”
BackgroundVascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery
Matsumoto, Y., Nichols, J. W., Toh, K., Nomoto, T., Cabral, H., Miura, Y., Christie, R. J., Yamada, N., Ogura, T., Kano, M. R., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.342 · Cited by 412 · cited 1×
“When moving from the periphery to the center of tumors, drugs face heterogenous vessel stress and collapse due to proliferating cells as the density of tumor and interstitial fluid pressure increase that further hinders the transport of drug molecules [80].”
BackgroundThe next frontier of molecular medicine: Delivery of therapeutics
Jain, R. K. (1998) · Nature Medicine · doi:10.1038/nm0698-655 · Cited by 407
Paradoxical glomerular filtration of carbon nanotubes
Ruggiero, A., Villa, C. H., Bander, E., Rey, D. A., Bergkvist, M., Batt, C. A., Manova-Todorova, K., Deen, W. M., Scheinberg, D. A., & McDevitt, M. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913667107 · Cited by 404 · cited 1×
“Porous media can aid in the filtration process [63].”
BackgroundMcKee, T. D., Grandi, P., Mok, W., Alexandrakis, G., Insin, N., Zimmer, J. P., Bawendi, M. G., Boucher, Y., Breakefield, X. O., & Jain, R. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2242 · Cited by 397 · cited 1×
“Preclinical models have shown increased accumulation and retention of the nanoparticles and oncolytic viruses with these approaches [45,49,50].”
BackgroundLee, H., Shields, A. F., Siegel, B. A., Miller, K. D., Krop, I., Ma, C. X., LoRusso, P. M., Munster, P. N., Campbell, K., Gaddy, D. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3193 · Cited by 393 · cited 1×
“64Cu-labelled, HER2-targeted PEGylated liposomes containing doxorubicin were used to study the EPR effect in primary and metastatic breast cancers by quantitative PET imaging and biopsies to determine the doxorubicin accumulation in the tumor and therapeutic efficacy [172].”
MethodDual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy
Dilnawaz, F., Singh, A., Mohanty, C., & Sahoo, S. K. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.057 · Cited by 385 · cited 1×
“The nanoparticles were built of PLGA-mPEG polymer and showed prolonged circulation half-life and improved imaging effects [135,136].”
BackgroundNanoparticles for Biomedical Imaging: Fundamentals of Clinical Translation
Choi, H. S., & Frangioni, J. V. (2010) · Molecular Imaging · doi:10.2310/7290.2010.00031 · Cited by 351 · cited 2×
“However, for the optimal development of nanoparticles for enhanced drug delivery by EPR effect, multiple factors should be considered, including blood half-life of nanoparticles, minimal nonspecific delivery, and effective elimination from the body [108].”
BackgroundMiller, M. A., Gadde, S., Pfirschke, C., Engblom, C., Sprachman, M. M., Kohler, R. H., Yang, K. S., Laughney, A. M., Wojtkiewicz, G., Kamaly, N., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac6522 · Cited by 347
Maeda, H., Tsukigawa, K., & Fang, J. (2016) · Microcirculation · doi:10.1111/micc.12228 · Cited by 336 · cited 2×
“The characteristics of the EPR effect are at disposal for this method of targeting, including (i) defective architecture of blood vessels, known as a “leaky vasculature,” with large gaps (around 400 nm) between capillary endothelial cell linings; (ii) overproduction of vascular mediators including bradykinin and nitri…”
BackgroundMethodIzumchenko, E., Paz, K., Ciznadija, D., Sloma, I., Katz, A., Vasquez-Dunddel, D., Ben-Zvi, I., Stebbing, J., McGuire, W., Harris, W., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx416 · Cited by 332 · cited 1×
“Their findings suggested that these models accurately replicated the patient outcomes over a repetitive course of therapy, enabling an oncologist to assess the patient-specific cellular events [97].”
BackgroundEffect of the surface charge of liposomes on their uptake by angiogenic tumor vessels
Krasnici, S., Werner, A., Eichhorn, M. E., Schmitt‐Sody, M., Pahernik, S. A., Sauer, B., Schulze, B., Teifel, M., Michaelis, U., Naujoks, K., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.11108 · Cited by 313
Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells
Huang, B., Abraham, W. D., Zheng, Y., Bustamante López, S. C., Luo, S. S., & Irvine, D. J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5447 · Cited by 312 · cited 1×
“The iNPG system was effective in TNBC, MDA-MB-231, and 4T1 mouse models of metastasis [21,167].”
BackgroundSelective Filtering of Particles by the Extracellular Matrix: An Electrostatic Bandpass
Lieleg, O., Baumgärtel, R. M., & Bausch, A. R. (2009) · Biophysical Journal · doi:10.1016/j.bpj.2009.07.009 · Cited by 304 · cited 1×
“The diffusive coefficient in the tumor interstitium is lower than in simple solutions for colloids and several in vivo and ex vivo studies have shown the same [42,43].”
BackgroundTreat, L. H., McDannold, N., Zhang, Y., Vykhodtseva, N., & Hynynen, K. (2012) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2012.04.015 · Cited by 296 · cited 1×
“enhanced drug accumulation in a gliosarcoma model [155].”
BackgroundCurrent status and perspectives of patient-derived xenograft models in cancer research
Lai, Y., Wei, X., Lin, S., Qin, L., Cheng, L., & Li, P. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0470-7 · Cited by 295 · cited 1×
“To maximize the clinical outcomes of investigational cancer therapeutics, new strategies to mimic the individual tumors are required that closely recapitulate the patients’ responses to preclinical drug testing [95,96].”
BackgroundAn injectable nanoparticle generator enhances delivery of cancer therapeutics
Xu, R., Zhang, G., Mai, J., Deng, X., Segura-Ibarra, V., Wu, S., Shen, J., Liu, H., Hu, Z., Chen, L., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3506 · Cited by 280
Hansen, A. E., Petersen, A. L., Henriksen, J. R., Boerresen, B., Rasmussen, P., Elema, D. R., Rosenschöld, P. M. A., Kristensen, A. T., Kjær, A., & Andresen, T. L. (2015) · ACS Nano · doi:10.1021/acsnano.5b01324 · Cited by 277 · cited 1×
“Copper-64 containing PEGylated liposomes were also developed to clearly observe the EPR effect through PET imaging [138].”
BackgroundMarkedly Enhanced Permeability and Retention Effects Induced by Photo-immunotherapy of Tumors
Sano, K., Nakajima, T., Choyke, P. L., & Kobayashi, H. (2013) · ACS Nano · doi:10.1021/nn305011p · Cited by 263
Regulation of microvascular permeability by vascular endothelial growth factors*
Bates, D. O., Hillman, N. J., Williams, B., Neal, C. R., & Pocock, T. M. (2002) · Journal of Anatomy · doi:10.1046/j.1469-7580.2002.00066.x · Cited by 258
Duan, L., Yang, L., Jin, J., Yang, F., Liu, D., Hu, K., Wang, Q., Yue, Y., & Gu, N. (2020) · Theranostics · doi:10.7150/thno.37593 · Cited by 251 · cited 1×
“Common strategies utilizing the EPR effect [109].”
Salvador-Morales, C., Zhang, L., Langer, R., & Farokhzad, O. C. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.01.005 · Cited by 250 · cited 1×
“It also changes the opsonization profile of the nanoparticle [61].”
BackgroundTumor stroma: a complexity dictated by the hypoxic tumor microenvironment
Casazza, A., Di Conza, G., Wenes, M., Finisguerra, V, Deschoemaeker, S., & Mazzone, M. (2014) · Oncogene · doi:10.1038/onc.2013.121 · Cited by 243 · cited 1×
“The tumors with a poor prognosis (brain tumors, renal carcinomas) have a fibrotic interstitium with more pericyte coverage (60–70%) as compared to tumors with better prognosis (ovarian carcinoma, colon cancers) with about a 10% coverage [81,82].”
BackgroundCycling hypoxia: A key feature of the tumor microenvironment
Michiels, C., Tellier, C., & Feron, O. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.06.004 · Cited by 237 · cited 1×
“The resulting hypoxic parts of tumors alter the EPR effect by activation of fibrinolysis, clotting, or bleeding in some tumor parts, result in poor delivery of drugs [65,71].”
BackgroundDevelopment of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls
Nakamura, H., Jun, F., & Maeda, H. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.955011 · Cited by 232 · cited 1×
“The characteristics of the EPR effect are at disposal for this method of targeting, including (i) defective architecture of blood vessels, known as a “leaky vasculature,” with large gaps (around 400 nm) between capillary endothelial cell linings; (ii) overproduction of vascular mediators including bradykinin and nitri…”
MethodZhou, W., Chen, C., Shi, Y., Wu, Q., Gimple, R. C., Fang, X., Huang, Z., Zhai, K., Ke, S. Q., Ping, Y.-F., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.10.002 · Cited by 231 · cited 1×
“Their findings suggest that adequate synergism can be established by combining this treatment with some poorly penetrating anticancer drugs [83].”
BackgroundExpert opinion: Responsive polymer nanoparticles in cancer therapy
Liechty, W. B., & Peppas, N. A. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.08.004 · Cited by 226 · cited 1×
“Studies have indicated that a nanoparticle size range of approximately 40 to 400 nm is suitable to ensure long circulation time, and enhanced accumulation in tumors with reduced renal clearance [6].”
BackgroundFang, J., Sawa, T., & Maeda, H. (2005) · Advances in Experimental Medicine and Biology · doi:10.1007/0-306-47932-x_2 · Cited by 221
(2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1171 · Cited by 219
Self-citationHypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells
Xing, F., Okuda, H., Watabe, M., Kobayashi, A., Pai, S. K., Liu, W., Pandey, P. R., Fukuda, K., Hirota, S., Sugai, T., et al. (2011) · Oncogene · doi:10.1038/onc.2011.122 · Cited by 219
van Vlerken, L. E., Duan, Z., Seiden, M. V., & Amiji, M. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1648 · Cited by 214
Wu, J., Akaike, T., & Maeda, H. (1998) · PubMed · Cited by 212
Enhancement of fluid filtration across tumor vessels: Implication for delivery of macromolecules
Netti, P. A., Hamberg, L. M., Babich, J. W., Kierstead, D., Graham, W., Hunter, G. J., Wolf, G. L., Fischman, A., Boucher, Y., & Jain, R. K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3137 · Cited by 202 · cited 2×
“Interstitial hydrodynamic and oncotic pressures play a key role in the convection of nanoparticles through the vascular wall, which are directly affected by the haphazard traffic of fluids [41].”
BackgroundSchmitt‐Sody, M., Strieth, S., Krasnici, S., Sauer, B., Schulze, B. G., Teifel, M., Michaelis, U., Naujoks, K., & Dellian, M. (2003) · PubMed · Cited by 192
In vivo assembly of nanoparticle components to improve targeted cancer imaging
Perrault, S. D., & Chan, W. C. W. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001367107 · Cited by 181 · cited 1×
“Fluorescent peptides that form nanoparticles in situ in tumors, and treatment responses that can be detected by imaging, have been developed [165].”
BackgroundTwo-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumors
Alexandrakis, G., Brown, E. B., Tong, R. T., McKee, T. D., Campbell, R. B., Boucher, Y., & Jain, R. K. (2004) · Nature Medicine · doi:10.1038/nm981 · Cited by 178 · cited 2×
“The diffusive coefficient in the tumor interstitium is lower than in simple solutions for colloids and several in vivo and ex vivo studies have shown the same [42,43].”
BackgroundExploring the Tumor Microenvironment with Nanoparticles
Miao, L., & Huang, L. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-16555-4_9 · Cited by 173 · cited 1×
“The tumors with a poor prognosis (brain tumors, renal carcinomas) have a fibrotic interstitium with more pericyte coverage (60–70%) as compared to tumors with better prognosis (ovarian carcinoma, colon cancers) with about a 10% coverage [81,82].”
BackgroundInvolvement of the Kinin‐generating Cascade in Enhanced Vascular Permeability in Tumor Tissue
Matsumura, Y., Kimura, M., Yamamoto, T., & Maeda, H. (1988) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1988.tb01563.x · Cited by 163 · cited 2×
“Moreover, the administration of angiotensin converting enzyme (ACE) inhibitors such as enalapril resulted in an increased accumulation of antibodies [2].”
BackgroundHuman Tumor Xenograft Models for Preclinical Assessment of Anticancer Drug Development
Jung, J. (2014) · Toxicological Research · doi:10.5487/tr.2014.30.1.001 · Cited by 158 · cited 1×
“To maximize the clinical outcomes of investigational cancer therapeutics, new strategies to mimic the individual tumors are required that closely recapitulate the patients’ responses to preclinical drug testing [95,96].”
BackgroundTheranostic USPIO‐Loaded Microbubbles for Mediating and Monitoring Blood‐Brain Barrier Permeation
Lammers, T., Koczera, P., Fokong, S., Gremse, F., Ehling, J., Vogt, M., Pich, A., Storm, G., van Zandvoort, M., & Kiessling, F. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201401199 · Cited by 156 · cited 1×
“However, sonoporation prompted a spatially and temporally controlled BBB opening facilitating enhanced drug delivery [154].”
BackgroundParameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection
Natfji, A. A., Ravishankar, D., Osborn, H. M. I., & Greco, F. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.06.019 · Cited by 155 · cited 1×
“Thus, complete control and performance monitoring throughout therapy might help develop successful clinical trials [69,70].”
BackgroundLee, S., Han, H., Koo, H., Na, J. H., Yoon, H. Y., Lee, K. E., Lee, H., Kim, H., Kwon, I. C., & Kim, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.02.035 · Cited by 154
Stylianopoulos, T., Soteriou, K., Fukumura, D., & Jain, R. K. (2012) · Annals of Biomedical Engineering · doi:10.1007/s10439-012-0630-4 · Cited by 151 · cited 1×
“This phenomenon has been exploited for therapeutic purposes by targeting an endothelial tumor vessel with anti-angiogenic and antitumor drugs in preclinical and clinical models [33,127].”
BackgroundOptical Imaging of Cancer Heterogeneity with Multispectral Optoacoustic Tomography
Herzog, E., Taruttis, A., Bézière, N., Lutich, A. A., Razansky, D., & Ntziachristos, V. (2012) · Radiology · doi:10.1148/radiol.11111646 · Cited by 151 · cited 1×
“Diagnostic techniques such as fluorescence imaging, positron emission tomography (PET), magnetic resonance imaging (MRI), computed tomography (CT), or single-photon emission computed tomography (SPECT) require delivery of small molecules to a tumor site, which is a challenging task [133,134].”
BackgroundPang, M.-F., Siedlik, M. J., Han, S., Stallings‐Mann, M. L., Radisky, D. C., & Nelson, C. M. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0579 · Cited by 146
Recent advances in drug delivery systems for enhancing drug penetration into tumors
He, B., Sui, X., Yu, B., Wang, S., Shen, Y., & Cong, H. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1831106 · Cited by 146 · cited 1×
“Thus, complementary active targeting with passive targeting, enhancing circulation, tumor accumulation, drug penetration in the target cell and finally release into the cytoplasm for action through circulation, accumulation, penetration, internalization, and release (CAPIR) cascade to improve the EPR effect is necessa…”
BackgroundIntrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy
Talelli, M., Oliveira, S., Rijcken, C. J. F., Pieters, E. H. E., Etrych, T., Ulbrich, K., van Nostrum, R., Storm, G., Hennink, W. E., & Lammers, T. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.064 · Cited by 142 · cited 1×
“Trastuzumab, together with different chemotherapeutics, are used for the treatment of HER2-positive metastatic breast cancer [161].”
BackgroundPark, J. S., Qiao, L., Su, Z.-Z., Hinman, D., Willoughby, K. A., McKinstry, R. P., Yacoub, A., Duigou, G. J., Young, C. S. H., Grant, S., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204258 · Cited by 139 · cited 1×
“Radiation therapy can increase vascular leakiness through upregulation of fibroblast growth factor [148].”
BackgroundTumor stroma–targeted antibody-drug conjugate triggers localized anticancer drug release
Szot, C. S., Saha, S., Zhang, X. M., Zhu, Z., Hilton, M. B., Morris, K., Seaman, S., Dunleavey, J. M., Hsu, K.-S., Yu, G., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120481 · Cited by 134 · cited 1×
“ADC might overcome heterogeneity of tumors by utilizing TME to facilitate cleavage of linkers and payload release [16].”
MethodGébleux, R., Stringhini, M., Casanova, R., Soltermann, A., & Neri, D. (2016) · International Journal of Cancer · doi:10.1002/ijc.30569 · Cited by 131 · cited 1×
“Gebleux and coworkers proposed non-internalizing antibody drug conjugates, ADC, that rely on extracellular release of drug thus preventing antigen barriers [15].”
BackgroundCD24 Is an Effector of HIF-1–Driven Primary Tumor Growth and Metastasis
Thomas, S., Harding, M. A., Smith, S. C., Overdevest, J. B., Nitz, M. D., Frierson, H. F., Tomlins, S. A., Kristiansen, G., & Theodorescu, D. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3666 · Cited by 128
Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy
Pérez-Medina, C., Abdel-Atti, D., Tang, J., Zhao, Y., Fayad, Z. A., Lewis, J. S., Mulder, W. J. M., & Reiner, T. (2016) · Nature Communications · doi:10.1038/ncomms11838 · Cited by 128 · cited 1×
“The accumulation of polystyrene nanoparticles in different tumor models has been evaluated using multi-modal imaging techniques [170].”
Cancer nanomedicine: Addressing the dark side of the enhanced permeability and retention effect
Huynh, E., & Zheng, G. (2015) · Nanomedicine · doi:10.2217/nnm.15.86 · Cited by 125 · cited 4×
“Age differences between human and mouse may further affect the EPR, as mice at a very young age are usually selected for tumor inoculation and tumors grow rapidly However, human tumors, at old age, may grow slowly and progress only over several years [5,20].”
BackgroundInfluentialLammers, T., Peschke, P., Kühnlein, R., Subr, V., Ulbrich, K., Debus, J., Huber, P., Hennink, W., & Storm, G. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.10.032 · Cited by 124 · cited 1×
“Thus, hyperthermia can be used to enhance EPR-mediated drug delivery, especially in non-leaky tumors with a very low level of baseline nanodrug accumulation [151].”
BackgroundNassiri, M., Babina, M., Dölle-Bierke, S., Edenharter, G., Ruëff, F., & Worm, M. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.09.004 · Cited by 124
Wang, Y., Ng, Y. W., Chen, Y., Shuter, B., Yi, J., Ding, J., Wang, S., & Feng, S. (2008) · Advanced Functional Materials · doi:10.1002/adfm.200700456 · Cited by 123 · cited 1×
“The nanoparticles were built of PLGA-mPEG polymer and showed prolonged circulation half-life and improved imaging effects [135,136].”
BackgroundCurrent Status of Hybrid PET/MRI in Oncologic Imaging
Rosenkrantz, A. B., Friedman, K. P., Chandarana, H., Melsaether, A. N., Moy, L. P., Ding, Y., Jhaveri, K. L., Beltrán, L., & Jain, R. (2015) · American Journal of Roentgenology · doi:10.2214/ajr.15.14968 · Cited by 121 · cited 1×
“Diagnostic techniques such as fluorescence imaging, positron emission tomography (PET), magnetic resonance imaging (MRI), computed tomography (CT), or single-photon emission computed tomography (SPECT) require delivery of small molecules to a tumor site, which is a challenging task [133,134].”
BackgroundCancer stromal targeting (CAST) therapy
Matsumura, Y. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.010 · Cited by 113 · cited 6×
“For instance, in the use of the ADC (antibody-drug conjugate) drugs with a scaffold for cancer (CA) stromal (S) targeting (T) (CAST) [10].”
BackgroundInfluentialMercatali, L., Manna, F. L., Groenewoud, A., Casadei, R., Recine, F., Miserocchi, G., Pieri, F., Liverani, C., Bongiovanni, A., Spadazzi, C., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081375 · Cited by 112
Pan, J., Mendes, L. P., Yao, M., Filipczak, N., Garai, S., Thakur, G. A., Sarısözen, C., & Torchilin, V. P. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.01.006 · Cited by 112 · cited 1×
“To reduce the toxicity of a PEI-based delivery system, polyethyleneimine is most often combined with other polymers such as PEG [129] or dendrimers [130].”
BackgroundSelf-citationWang, Y., Wang, Z., Xu, C., Tian, H., & Chen, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.01.025 · Cited by 110 · cited 1×
“FeTNPs are characterized by their effective accumulation in tumor tissue based on the EPR effect and the possibility of being disassembled dynamically by deferoxamine mesylate (DFO) to accelerate the elimination of nanoparticles, thus reducing the potential for toxicity [126].”
BackgroundLöhr, M. J., Haas, S., Bechstein, W. O., Bodoky, G., Cwiertka, K., Fischbach, W., Fölsch, U. R., Jäger, D., Osinsky, D., Prausová, J., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr379 · Cited by 108 · cited 1×
“This phenomenon has been exploited for therapeutic purposes by targeting an endothelial tumor vessel with anti-angiogenic and antitumor drugs in preclinical and clinical models [33,127].”
BackgroundBinnemars‐Postma, K., ten Hoopen, H., Storm, G., & Prakash, J. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0233 · Cited by 106 · cited 1×
“The ARBs can modulate the expression of ECM, leading to vessel decompression and an enhanced EPR [144].”
BackgroundIslam, W., Fang, J. Q., Imamura, T., Etrych, T., Šubr, V., Ulbrich, K., & Maeda, H. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0696 · Cited by 106
Li, F., Wang, Y., Chen, W., Wang, D., Zhou, Y., You, B., Liu, Y., Qu, C., Yang, S.-D., Chen, M., et al. (2019) · Theranostics · doi:10.7150/thno.32416 · Cited by 101
Yu, B., Goel, S., Ni, D., Ellison, P. A., Siamof, C. M., Jiang, D., Cheng, L., Kang, L., Yu, F., Liu, Z., et al. (2018) · Advanced Materials · doi:10.1002/adma.201704934 · Cited by 94 · cited 1×
“These radiolabeled liposomes showed enhanced EPR effects, improved photodynamics, and in vivo stability [137].”
BackgroundFang, J. Q., Qin, H., Nakamura, H., Tsukigawa, K., Shin, T., & Maeda, H. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02178.x · Cited by 88
HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery
Chytil, P., Kostka, L., & Etrych, T. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020115 · Cited by 87 · cited 1×
“Conjugates of HPMA copolymer with an anticancer drug are active in many models and have low immunogenicity, which makes it possible to improve such a conjugate to target and control its subcellular localization of the drug based on its mechanism of action [116,118,119].”
BackgroundYasunaga, M., Manabe, S., Tarin, D., & Matsumura, Y. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200158j · Cited by 84
Palanisamy, N., Yang, J., Shepherd, P. D. A., Li-Ning-Tapia, E. M., Labanca, E., Manyam, G. C., Ravoori, M. K., Kundra, V., Araujo, J. C., Efstathiou, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0479 · Cited by 84 · cited 1×
“Erdafitinib FGFR Metastatic prostate cancer Male mice [106]”
BackgroundBLIMP1 Induces Transient Metastatic Heterogeneity in Pancreatic Cancer
Chiou, S., Risca, V. I., Wang, G. X., Yang, D., Grüner, B. M., Kathiria, A. S., Ma, R. K., Vaka, D., Chu, P., Kozak, M. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0250 · Cited by 80
New concept of cytotoxic immunoconjugate therapy targeting cancer‐induced fibrin clots
Yasunaga, M., Manabe, S., & Matsumura, Y. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01954.x · Cited by 79 · cited 1×
“This newly developed immunoconjugate was optimized to bound with stromal collagen creating a scaffold with sustained release of anticancer agent [13,14].”
MethodRandall, E. C., Emdal, K. B., Laramy, J. K., Kim, M., Roos, A., Calligaris, D., Regan, M. S., Gupta, S. K., Mladek, A. C., Carlson, B. L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07334-3 · Cited by 79 · cited 1×
“Erlotinib EGFR Glioblastoma Athymic nude mice [100]”
Karageorgis, A., Dufort, S., Sancey, L., Henry, M., Hirsjärvi, S., Passirani, C., Benoît, J., Gravier, J., Texier, I., Montigon, O., et al. (2016) · Scientific Reports · doi:10.1038/srep21417 · Cited by 71 · cited 1×
“drug SN-38 to the T cell surface, used to traffic through the lymphatic system, resulted in a 90-fold increase of SN-38 drugs in lymph nodes relative to free drug [168].”
BackgroundPawlikowska, P., Tayoun, T., Oulhen, M., Faugeroux, V., Rouffiac, V., Aberlenc, A., Pommier, A.-L., Honoré, A., Marty, V., Bawa, O., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73632-w · Cited by 70 · cited 3×
“Numerous current publications reported the use of chick chorioallantoic membrane (CAM) and Zebrafish for implantation as alternatives to mice.”
BackgroundInterpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier-Mediated Anticancer Agents
Caron, W. P., Song, G. J., Kumar, P., Rawal, S., & Zamboni, W. C. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.12 · Cited by 68 · cited 1×
“This suggests that mononuclear phagocytes interact with nanoparticles, which could then affect the pharmacodynamics of the nanoparticles [47,48].”
BackgroundNakamura, H., Liao, L., Hitaka, Y., Tsukigawa, K., Šubr, V., Fang, J. Q., Ulbrich, K., & Maeda, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.11.017 · Cited by 67 · cited 1×
“Conjugates of HPMA copolymer with an anticancer drug are active in many models and have low immunogenicity, which makes it possible to improve such a conjugate to target and control its subcellular localization of the drug based on its mechanism of action [116,118,119].”
BackgroundSano, K., Nakajima, T., Choyke, P. L., & Kobayashi, H. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0633 · Cited by 66 · cited 2×
“The combination of an anti-PD-L1 with an immunogenic cell death-inducing nanoscale coordination polymer (NCP), loaded with oxaliplatin, as well as photosensitizer for PDT showed success in cancer therapy [157].”
BackgroundMethodFang, J. Q., Islam, R., Islam, W., Yin, H., Šubr, V., Etrych, T., Ulbrich, K., & Maeda, H. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11070343 · Cited by 66 · cited 1×
“Examples include the selective inhibition of angiotensin-converting enzymes [86,87], generation of NO or CO within tumors [56,87,88], blockage of VEGF and other angiogenic signaling factors [89–91], inhibition of pericyte recruitment and BM activation [92,93], and image guiding systems [94].”
BackgroundJoshi, U., Filipczak, N., Khan, M. M., Attia, S. A., & Torchilin, V. P. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119915 · Cited by 65 · cited 1×
“This strategy may allow for an effective supply of genetic material and can be used as a therapy for drug-resistant tumors [131,132].”
BackgroundSelf-citationMaeda, H. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.002 · Cited by 64
Yao, Y., Wang, T., Liu, Y., & Zhang, N. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1596943 · Cited by 60
The Current Landscape of Antibody-based Therapies in Solid Malignancies
Shah, A., Rauth, S., Aithal, A., Kaur, S., Ganguly, K., Orzechowski, C., Varshney, G. C., Jain, M., & Batra, S. K. (2020) · Theranostics · doi:10.7150/thno.52614 · Cited by 55 · cited 2×
“mAbs-based therapies are potential approaches to overcome these barriers using several diagnostic and prognostic biomarkers for envisaging response to mAb-based therapies [18].”
BackgroundPassive and Active Targeting in Tumor Microenvironment
Wakaskar, R. R. (2017) · International Journal of Drug Development and Research · Cited by 51
In-vitro and in-vivo difference in gene delivery by lithocholic acid-polyethyleneimine conjugate
Wang, J., Meng, F., Kim, B.-K., Ke, X., & Yeo, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119296 · Cited by 51 · cited 14×
“To date, the FDA has approved many other liposomal formulations such as DaunoXome®, which contains daunorubicin, and Marquibo®, which contains vincristine sulfate for cancer therapy [123] as well as other types of nanoparticle including polymeric micelles containing paclitaxel (Genexol® PM), micelles built with PEG an…”
BackgroundInfluentialHu, J., Ishihara, M., Chin, A. I., & Wu, L. (2019) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbz018 · Cited by 51 · cited 1×
“Hu and coworkers demonstrated that CAM is an efficient system to analyze pilot drug responses in patients with bladder tumors, accelerating the discovery of critical molecular mechanisms [98].”
BackgroundFang, J. Q., Liao, L., Yin, H., Nakamura, H., Shin, T., & Maeda, H. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24083 · Cited by 49 · cited 1×
“Examples include the selective inhibition of angiotensin-converting enzymes [86,87], generation of NO or CO within tumors [56,87,88], blockage of VEGF and other angiogenic signaling factors [89–91], inhibition of pericyte recruitment and BM activation [92,93], and image guiding systems [94].”
BackgroundWu, Q., Yuan, X., Bai, J., Han, R., Li, Z., Zhang, H., & Xiu, R. (2019) · Aging · doi:10.18632/aging.102171 · Cited by 47 · cited 1×
“Examples include the selective inhibition of angiotensin-converting enzymes [86,87], generation of NO or CO within tumors [56,87,88], blockage of VEGF and other angiogenic signaling factors [89–91], inhibition of pericyte recruitment and BM activation [92,93], and image guiding systems [94].”
BackgroundChoi, B., Lee, J. S., Kim, S. J., Hong, D.-P., Park, J. B., & Lee, K. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.042 · Cited by 47 · cited 2×
“Bortezomib CDK4 and MDM2 Liposarcoma Mice [104] Pembrolizumab PD-1/PD-L1 Soft Tissue Sarcoma NSG mice [105]”
BackgroundCancer stromal targeting therapy to overcome the pitfall of EPR effect
Matsumura, Y. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.003 · Cited by 47 · cited 5×
“Moreover, the CAST therapy might be another approach to compensate for the inadequate effect of the EPR targeting [14].”
BackgroundMethodInfluentialSulheim, E., Kim, J., van Wamel, A. J. E. T., Kim, E., Snipstad, S., Vidić, I., Grimstad, I. H., Widerøe, M., TORP, S. H., Lundgren, S., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.026 · Cited by 46 · cited 1×
“MRI scanning was used to characterize and correlate parameters including RBV and vessel permeability with the accumulation of fluorophore-labeled nanoparticles in several tumor models to detect biomarkers of EPR-mediated drug accumulation that have been studied [169].”
MethodHPMA Copolymer Delivery of Chemotherapy and Photodynamic Therapy in Ovarian Cancer
Peterson, C. M., Shiah, J.-G., Sun, Y., Kopečková, P., Minko, T., Straight, R. C., & Kopeček, J. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-47932-x_7 · Cited by 45
Zamboni, W. C., Maruca, L. J., Strychor, S., Zamboni, B. A., Ramalingam, S. S., Edwards, R. P., Kim, J., Bang, Y., Lee, H., Friedland, D., et al. (2010) · Journal of Liposome Research · doi:10.3109/08982104.2010.496085 · Cited by 45 · cited 1×
“This suggests that mononuclear phagocytes interact with nanoparticles, which could then affect the pharmacodynamics of the nanoparticles [47,48].”
BackgroundLessons from immuno-oncology: a new era for cancer nanomedicine?
Jiang, W., Yuan, H., Chan, C. K. F., Roemeling, C. A. V., Yan, Z., Weissman, I. L., & Kim, B. Y. S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.34 · Cited by 44
Tan, L., Wan, J., Guo, W., Ou, C., Liu, T., Fu, C., Zhang, Q., Ren, X., Liang, X., Ren, J., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.01.003 · Cited by 44 · cited 1×
“The disadvantage of this solution is that large-sized nanoparticles will be absorbed by organs of the reticuloendothelial system (RES), such as the liver and spleen, resulting in slower elimination from the body and a potential for toxicity [120].”
BackgroundWang, H., Lu, J., Wang, L., Chen, S., He, K., Jiang, X., Jiang, W., & Teng, L. (2017) · BMC Cancer · doi:10.1186/s12885-017-3177-9 · Cited by 43 · cited 1×
“Ramucirumab Her2, FGFR2, cMet Gastric cancers BALB/c nude mice [103]”
BackgroundTheek, B., Baues, M., Gremse, F., Pola, R., Pechar, M., Negwer, I., Koynov, K., Weber, B., Barz, M., Jahnen‐Dechent, W., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.002 · Cited by 43
Doleschel, D., Rix, A., Arns, S., Palmowski, K., Gremse, F., Merkle, R., Salopiata, F., Klingmüller, U., Jarsch, M., Kiessling, F. M., et al. (2015) · Theranostics · doi:10.7150/thno.11304 · Cited by 38 · cited 1×
“Similarly, erythropoietin in NSCLC models, increased vessel density by 50%, doubled the relative tissue blood volume, through the vessel promotion, which resulted in up to a 100% increased cisplatin delivery [147].”
BackgroundSpecific Targets in Tumor Tissue for the Delivery of Therapeutic Genes
Günther, M., Wagner, E., & Ogris, M. (2005) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011053174855 · Cited by 37 · cited 1×
“Similar to anticancer drugs, for specific tumor delivery of siRNA, sufficient longevity of loaded siRNA carriers is required [128].”
BackgroundWu, J., Fan, R.-Y., Zhang, S., Li, C.-Y., Shen, L., Wei, P., He, Z., & He, M. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117402 · Cited by 37 · cited 2×
“Apatinib, Regorafenib, Cabozantinib, Ramucirumab VEGFR2 Gastric cancers Zebrafish [102]”
BackgroundNoguchi, A., Takahashi, T., Yamaguchi, T., Kitamura, K., Noguchi, A., Tsurumi, H., Takashina, K., & Maeda, H. (1992) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1992.tb00093.x · Cited by 32 · cited 1×
“The ACE inhibitor blocked the degradation of bradykinin (a potent physiological vasodilatory peptide), which increased the permeability to large molecules [41,51].”
BackgroundCao, M., Long, M., Chen, Q., Lu, Y., Luo, Q., Zhao, Y., Lu, A., Cun-wang, G., Zhu, L., & Chen, Z. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2656-x · Cited by 32 · cited 2×
“β-elemene and cisplatin-coloaded liposomes Codelivery to reverse MDR Lung cancer C57BL/6 mice [107]”
BackgroundHori, Y., Ito, K., Hamamichi, S., Ozawa, Y., Matsui, J., Umeda, I. O., & Fujii, H. (2017) · Anticancer Research · doi:10.21873/anticanres.12120 · Cited by 32
Studenovský, M., Sivák, L., Sedláček, O., Konefał, R., Horková, V., Etrych, T., Kovář, M., Rihova, B., & Šírová, M. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.017 · Cited by 31 · cited 1×
“Examples include the selective inhibition of angiotensin-converting enzymes [86,87], generation of NO or CO within tumors [56,87,88], blockage of VEGF and other angiogenic signaling factors [89–91], inhibition of pericyte recruitment and BM activation [92,93], and image guiding systems [94].”
BackgroundZamboni, W. C., Eiseman, J. L., Strychor, S., Rice, P. M., Joseph, E., Zamboni, B. A., Donnelly, M. K., Shurer, J., Parise, R. A., Tonda, M. E., et al. (2010) · Journal of Liposome Research · doi:10.3109/08982101003754385 · Cited by 28 · cited 1×
“showed that increased liposomal accumulation was seen in xenografts of ovarian cancer with increased CD11 positive cells in comparison to melanoma cells with lower dendritic cell expression [37].”
ResultErgen, C., Niemietz, P. M., Heymann, F., Baues, M., Gremse, F., Pola, R., van Bloois, L., Storm, G., Kiessling, F., Trautwein, C., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.03.025 · Cited by 27 · cited 1×
“Examples include the selective inhibition of angiotensin-converting enzymes [86,87], generation of NO or CO within tumors [56,87,88], blockage of VEGF and other angiogenic signaling factors [89–91], inhibition of pericyte recruitment and BM activation [92,93], and image guiding systems [94].”
BackgroundHypoxia-Responsive Copolymer for siRNA Delivery
Perche, F., Biswas, S., Patel, N. R., & Torchilin, V. P. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3148-4_12 · Cited by 26 · cited 1×
“This strategy may allow for an effective supply of genetic material and can be used as a therapy for drug-resistant tumors [131,132].”
BackgroundSelf-citationCancer Drug Delivery Systems Based on the Tumor Microenvironment
Atsushi, T., & Tsuneo, S. (2019) · Springer eBooks · doi:10.1007/978-4-431-56880-3 · Cited by 17
Islam, R., Gao, S., Islam, W., Šubr, V., Zhou, J.-R., Yokomizo, K., Etrych, T., Maeda, H., & Fang, J. Q. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.03.044 · Cited by 13 · cited 1×
“As a fascinating result, intralipid pretreatment prolonged the plasma half-life of nanomedicines in normal healthy mice but not in tumor-bearing mice, which suggests that tumors may be an alternative route of nanodrug delivery when liver delivery is suppressed [158].”
BackgroundJo, E. B., Hong, D.-P., Lee, Y. S., Lee, H., Park, J. B., & Kim, S. J. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.09.015 · Cited by 12 · cited 3×
“Bortezomib CDK4 and MDM2 Liposarcoma Mice [104] Pembrolizumab PD-1/PD-L1 Soft Tissue Sarcoma NSG mice [105]”
Background
Research works printed but not linked: 1
- Dellian, 2000, Vascular permeability in a human tumour xenograft: Molecular charge dependence, Br. J. Cancer, 82, 1513
Cited by
Effects of nanoparticle size, shape, and zeta potential on drug delivery
Öztürk, K., Kaplan, M., & Çalış, S. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124799 · Cited by 449
Nanotechnology in healthcare, and its safety and environmental risks
Ma, X., Tian, Y., Yang, R., Wang, H., Allahou, L. W., Chang, J., Williams, G., Knowles, J. C., & Poma, A. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02901-x · Cited by 332
Strategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330
Bajracharya, R., Song, J. G., Patil, B. R., Lee, S. H., Noh, H.-M., Kim, D.-H., Kim, G.-L., Seo, S.-H., Park, J.-W., Jeong, S. H., et al. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2089296 · Cited by 246
“In comparison to free drugs, nano-DDS have hydrodynamic diameters exceeding the renal clearance threshold and have prolonged circulation in the blood, which leads to extravasation from leaky tumor vessels (Golombek et al., 2018; Subhan et al., 2021).”
BackgroundEnhancement of EPR Effect for Passive Tumor Targeting: Current Status and Future Perspectives
Vagena, I.-A., Malapani, C., Gatou, M.-A., Lagopati, N., & Pavlatou, E. A. (2025) · Applied Sciences · doi:10.3390/app15063189 · Cited by 220
Metadata
- Authors
- Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P.
- Affiliations
- Shahjalal University of Science and Technology (BD)
- Northeastern University (US)
- Corresponding author
- Subhan, Md Abdus
- Torchilin, Vladimir P.
- ORCID
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2021-06-18
- Volume
- 11
- Issue
- 6
- Pages
- 571
- ISSN
- 2075-4426 (ISSN-L)
- PMC
- PMC8234032
- OpenAlex
- W3174294541
- Semantic Scholar
- 0e274cc5538c8ce64b42706c752e9cd357ce4ede
- Cited by
- 623
- References
- 172
- Citations by year
- 2026: 116 · 2025: 167 · 2024: 148 · 2023: 106 · 2022: 82 · 2021: 4
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Personalized Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
- Keywords
- enhanced permeability and retention effect, tumor targeting, cancer nanomedicine, nanotherapeutics, tumor selectivity, intravenous drug delivery, tumor microenvironment, lymphatic drainage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.